The MYC/BCL2 double expression was also more enriched in the old subgroup (23.8% vs. 10.3%, p < 0.05), whereas no significant differences were found between the old and young subgroups in serum LDH level, Ann Arbor stage, primary tumor site, the number of extranodal tumors, and COO. This evidence concerns the gene BCL2 and neoplasm.